BACKGROUND: Psychotropic medications are commonly used for depressive symptoms among people living with HIV/AIDS. PURPOSE: We examined the relationships between adherence to psychotropic medications, depressive symptoms, and antiretroviral adherence. METHODS: We assessed depressive symptoms among 324 people living with HIV/AIDS across a 3-month period (70% men; mean age 45 years; 90% African-American). Psychotropic and antiretroviral adherence was assessed using monthly, unannounced telephone pill counts. Multiple-regression and mediation analyses were utilized to examine associations under investigation. RESULTS: Greater depressive symptoms were associated with lower antiretroviral and psychotropic medication adherence. Greater adherence to psychotropic medications regardless of medication class was positively related to higher antiretroviral adherence. Greater adherence to psychotropic medications also significantly mediated the association between depressive symptoms and antiretroviral adherence. CONCLUSIONS: This study demonstrates the benefits of adherence to psychotropic medications on both depressive symptoms and antiretroviral adherence. Future work examining psychotropic medication adherence on disease outcomes in people living with HIV/AIDS is warranted.
BACKGROUND: Psychotropic medications are commonly used for depressive symptoms among people living with HIV/AIDS. PURPOSE: We examined the relationships between adherence to psychotropic medications, depressive symptoms, and antiretroviral adherence. METHODS: We assessed depressive symptoms among 324 people living with HIV/AIDS across a 3-month period (70% men; mean age 45 years; 90% African-American). Psychotropic and antiretroviral adherence was assessed using monthly, unannounced telephone pill counts. Multiple-regression and mediation analyses were utilized to examine associations under investigation. RESULTS: Greater depressive symptoms were associated with lower antiretroviral and psychotropic medication adherence. Greater adherence to psychotropic medications regardless of medication class was positively related to higher antiretroviral adherence. Greater adherence to psychotropic medications also significantly mediated the association between depressive symptoms and antiretroviral adherence. CONCLUSIONS: This study demonstrates the benefits of adherence to psychotropic medications on both depressive symptoms and antiretroviral adherence. Future work examining psychotropic medication adherence on disease outcomes in people living with HIV/AIDS is warranted.
Authors: Margherita Dalessandro; Chiara M Conti; Francesco Gambi; Katia Falasca; Robert Doyle; Pio Conti; Francesco Caciagli; Mario Fulcheri; Jacopo Vecchiet Journal: J Clin Psychopharmacol Date: 2007-02 Impact factor: 3.153
Authors: Julia H Arnsten; Xuan Li; Yuko Mizuno; Amy R Knowlton; Marc N Gourevitch; Kathleen Handley; Kelly R Knight; Lisa R Metsch Journal: J Acquir Immune Defic Syndr Date: 2007-11-01 Impact factor: 3.731
Authors: Michael Alan Horberg; Michael Jonah Silverberg; Leo Bartemeier Hurley; William James Towner; Daniel Benjamin Klein; Susan Bersoff-Matcha; Winkler Gabriel Weinberg; Diana Antoniskis; Miguel Mogyoros; Wayne Thomas Dodge; Robert Dobrinich; Charles Price Quesenberry; Drew Anthony Kovach Journal: J Acquir Immune Defic Syndr Date: 2008-03-01 Impact factor: 3.731
Authors: Seth C Kalichman; Christina M Amaral; Chauncey Cherry; Jody Flanagan; Howard Pope; Lisa Eaton; Moira O Kalichman; Demetria Cain; Mervi Detorio; Angela Caliendo; Raymond F Schinazi Journal: HIV Clin Trials Date: 2008 Sep-Oct
Authors: Kaitlin B Casaletto; Sara Kwan; Jessica L Montoya; Lisa C Obermeit; Ben Gouaux; Amelia Poquette; Robert K Heaton; J Hampton Atkinson; David J Moore Journal: Int J Psychiatry Med Date: 2016 Impact factor: 1.210
Authors: Robert Gross; Scarlett L Bellamy; Jennifer Chapman; Xiaoyan Han; Jacqueline O'Duor; Brian L Strom; Peter S Houts; Steven C Palmer; James C Coyne Journal: PLoS One Date: 2014-01-06 Impact factor: 3.240